MGTX vs. BEAM, IDYA, AGIO, IOVA, TARS, AKRO, BLTE, IRON, AMPH, and WVE
Should you be buying MeiraGTx stock or one of its competitors? The main competitors of MeiraGTx include Beam Therapeutics (BEAM), IDEAYA Biosciences (IDYA), Agios Pharmaceuticals (AGIO), Iovance Biotherapeutics (IOVA), Tarsus Pharmaceuticals (TARS), Akero Therapeutics (AKRO), Belite Bio (BLTE), Disc Medicine (IRON), Amphastar Pharmaceuticals (AMPH), and Wave Life Sciences (WVE). These companies are all part of the "pharmaceutical products" industry.
MeiraGTx vs.
Beam Therapeutics (NASDAQ:BEAM) and MeiraGTx (NASDAQ:MGTX) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their profitability, earnings, analyst recommendations, community ranking, media sentiment, institutional ownership, dividends, valuation and risk.
Beam Therapeutics has a net margin of -41.07% compared to MeiraGTx's net margin of -633.05%. Beam Therapeutics' return on equity of -16.22% beat MeiraGTx's return on equity.
Beam Therapeutics presently has a consensus target price of $47.67, suggesting a potential upside of 74.73%. MeiraGTx has a consensus target price of $23.50, suggesting a potential upside of 265.47%. Given MeiraGTx's higher probable upside, analysts plainly believe MeiraGTx is more favorable than Beam Therapeutics.
99.7% of Beam Therapeutics shares are held by institutional investors. Comparatively, 67.5% of MeiraGTx shares are held by institutional investors. 4.2% of Beam Therapeutics shares are held by insiders. Comparatively, 8.4% of MeiraGTx shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
Beam Therapeutics has a beta of 1.92, meaning that its stock price is 92% more volatile than the S&P 500. Comparatively, MeiraGTx has a beta of 1.26, meaning that its stock price is 26% more volatile than the S&P 500.
In the previous week, Beam Therapeutics had 13 more articles in the media than MeiraGTx. MarketBeat recorded 16 mentions for Beam Therapeutics and 3 mentions for MeiraGTx. MeiraGTx's average media sentiment score of 0.85 beat Beam Therapeutics' score of 0.68 indicating that MeiraGTx is being referred to more favorably in the news media.
MeiraGTx received 135 more outperform votes than Beam Therapeutics when rated by MarketBeat users. Likewise, 71.54% of users gave MeiraGTx an outperform vote while only 56.00% of users gave Beam Therapeutics an outperform vote.
MeiraGTx has lower revenue, but higher earnings than Beam Therapeutics. Beam Therapeutics is trading at a lower price-to-earnings ratio than MeiraGTx, indicating that it is currently the more affordable of the two stocks.
Summary
Beam Therapeutics and MeiraGTx tied by winning 9 of the 18 factors compared between the two stocks.
Get MeiraGTx News Delivered to You Automatically
Sign up to receive the latest news and ratings for MGTX and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
MeiraGTx Competitors List
Related Companies and Tools
This page (NASDAQ:MGTX) was last updated on 1/30/2025 by MarketBeat.com Staff
